- Home
- AGAE vs ACXP Comparison
AGAE vs ACXP Comparison
Compare AGAE & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGAE | ACXP |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 6.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AGAE | ACXP |
|---|---|---|
| Price | $0.35 | $3.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $143.67 |
| AVG Volume (30 Days) | ★ 1.1M | 79.9K |
| Earning Date | 11-19-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,938,232.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.34 | $3.17 |
| 52 Week High | $3.79 | $25.00 |
Technical Indicators
Market Signals| Indicator | AGAE | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 34.21 | 41.03 |
| Support Level | $0.34 | $3.98 |
| Resistance Level | $0.40 | $4.36 |
| Average True Range (ATR) | 0.04 | 0.37 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 0.00 | 29.30 |
Price Performance
Historical ComparisonAbout AGAE Allied Gaming & Entertainment Inc.
Allied Gaming & Entertainment Inc is an experiential entertainment company focused on providing a growing world of gamers with various experiences through renowned assets, products, and services.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.